Nuclear Medicine & Radiation Therapy

David JL Joske

Publications

• Research Article
  Iodine-131 Rituximab Radioimmunotherapy: Durable Control of Follicular Lymphoma
  Author(s): Paul C Kruger, David JL Joske and Harvey Turner JPaul C Kruger, David JL Joske and Harvey Turner J
  
  Abstract Aims: We evaluated the response and toxicity, after long-term follow up of Iodine-131 rituximab radioimmunotherapy in patients with follicular lymphoma under the routine clinical care of a single hematologist over a period of 12 years. Materials and methods: Patients received 131I-rituximab radioimmunotherapy according to a standard, personalized dosimetry protocol predicated upon a prescribed whole body radiation absorbed dose of 0.75Gy. Four doses of maintenance rituximab were subsequently administered over 12 months.   Results: Response rate was 97% with 24(77%) patients experiencing a complete remission confirmed on 18F-fluorodeoxyglucose positron emission tomography-computerized tomography scan. The cohort of 3 patients with duodenal lymphoma all achieved complete remission lasting 4-5 years. Disclosure statement: T.. Read More»
  DOI: 10.4172/2155-9619.1000191

  Abstract PDF